Boehringer touts Pradaxa antidote data as FDA decision nears

LONDON--Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson ($JNJ) and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker is hoping a nod for its antidote candidate will help turn the tide in its favor. On Tuesday, the company touted positive data in support of that candidate: In 39 patients who required emergency surgery, the experimental antidote, idarucizumab, reversed the effects of Pradaxa with a median 1.7 hours between administering the drug and starting a procedure, a late-stage trial analysis showed. More from FiercePharmaMarketing